背景:肝细胞癌(HCC)是全球癌症相关死亡的主要原因。这项研究旨在提供一个全面的调查,以筛选和确定预测HCC的生物标志物。
方法:首先,生物信息学技术用于筛选潜在的肝癌相关基因,评估BZW2、CDT1、IVD表达与生存率及临床病理因素的关系。之后,qRT-PCR,采用westernblot和免疫组织化学方法验证BZW2,CDT1和IVD在临床切除的癌症标本中的表达。此外,体外试验,细胞周期,凋亡,进行集落形成和划痕实验以检测si-BZW2,si-CDT1和oe-IVD在HCC细胞中的作用。体内实验,测量肿瘤体积和重量以评估si-BZW2、si-CDT1和oe-IVD在携带HCC肿瘤的小鼠中的抗肿瘤作用。
结果:生物信息学分析表明,BZW2、CDT1高表达和IVD低表达的HCC患者预后差,临床病理因素不利。同样,临床样本分析显示,HCC组织中BZW2和CDT1表达增加,而IVD表达降低。同时,体外实验发现si-BZW2、si-CDT1和oe-IVD促进肝癌细胞凋亡,抑制细胞集落形成和迁移。不出所料,体内实验表明,si-BZW2,si-CDT1和oe-IVD可以抑制肿瘤的生长。
结论:增加BZW2,CDT1水平,降低的IVD水平可以作为预测HCC的生物标志物。此外,靶向BZW2、CDT1和IVD可能为治疗HCC提供新的方法.
Hepatocellular carcinoma (HCC) is the leading cause of cancer-related deaths globally. This study aimed to provide a comprehensive investigation to screen and identify biomarkers for predicting HCC.
Firstly, the bioinformatics technique was applied to screen potential HCC-related genes, and the relationships between BZW2, CDT1, IVD expression and survival rate and clinicopathological factors were assessed. Afterward, qRT-PCR, western blot and immunohistochemistry were employed to validate the expression of BZW2, CDT1, and IVD in clinical resected cancer specimens. Furthermore, in vitro assays, cell cycle, apoptosis, colony formation and scratch experiments were performed to detect the effects of si-BZW2, si-
CDT1 and oe-IVD in HCC cells. In vivo experiments, tumor volume and weight were measured to assess the anti-tumor effect of si-BZW2, si-
CDT1 and oe-IVD in HCCtumor- bearing mice.
Bioinformatics analysis indicated that HCC patients with high expression of BZW2, CDT1 and low expression of IVD have a poor prognosis and unfavorable clinicopathological factors. Similarly, clinical sample analysis revealed that BZW2 and CDT1 expression were increased while IVD expression was decreased in HCC tissues. Meanwhile, in vitro experiments found that si-BZW2, si-
CDT1 and oe-IVD promoted apoptosis and inhibited the colony formation and migration of HCC cells. As expected, in vivo experiments demonstrated that si-BZW2, si-CDT1 and oe-IVD could inhibit tumor growth.
Increased BZW2,
CDT1 levels, and decreased IVD levels could act as biomarkers for predicting HCC. Furthermore, targeting BZW2,
CDT1, and IVD may offer a new approach to treat HCC.